Xtant Medical Holdings, Inc.
AMEX:XTNTMedical - Devices
-$0.00 today
- Market cap
- $50.37M
- Beta
- -0.17
- P/E (TTM)
- 33.4
- EPS (TTM)
- $0.01
Volume 0.16M
Average 0.16M
XTNT Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Xtant Medical Holdings, Inc.AMEX: XTNT
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit dips below year-ago levels
Q1 FY2026 gross profit of $11.97M fell 40.9% year over year, behind the +6.8% change in trailing-twelve-month gross profit. Sequentially, it fell 32.6% from the prior quarter. Over 3 fiscal years it compounded at +37.9% a year.
Context
- Gross profit amounted to 62.9% of revenue in FY2025, up 4.8 pp from a year earlier.
- Gross profit increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -40.9% toward the trailing-twelve-month pace of +6.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 84.27M USD
- Year-over-year change
- +23.5%
- 4-year CAGR
- +26.9%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 84.27M | +23.5% |
| FY2024 | 2024-12-31 | 68.22M | +23.0% |
| FY2023 | 2023-12-31 | 55.47M | +72.6% |
| FY2022 | 2022-12-31 | 32.14M | -1.1% |
| FY2021 | 2021-12-31 | 32.49M | — |
Gross Profit vs competitors
How XTNT compares with its peers on the latest reported figures
- XTNT's LTM Mar 2026 gross profit of $76M is the highest of the 8 companies compared; the peer median is $4.26M.
- Its year-over-year change of +6.8% is the 4th highest of 8, against a peer median of -0.1%.
- Gross profit amounts to 62.3% of revenue for XTNT, versus a peer median of 40.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $76M | +6.8% | +37.9% | 62.3% | |
| LTM Mar 2026 | $58.86M | -3.9% | +27.5% | 81.4% | |
| LTM Mar 2026 | $42.41M | -0.1% | -3.0% | 40.3% | |
| LTM Mar 2026 | $18.04M | -26.0% | -13.2% | 32.3% | |
| LTM Mar 2026 | $4.26M | +134.5% | — | 12.4% | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | -$3.64K | +98.7% | — | — |
| LTM Mar 2026 | -$130K | -46.1% | — | — | |
| LTM Mar 2026 | -$2.06M | +27.2% | — | 40.0% | |
| Peer median (excluding XTNT) | $4.26M | -0.1% | -3.0% | 40.0% | |
Competitors are the stored peer set for XTNT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.26M | 57.97M | 91.3M | 117.27M | 133.93M |
| Cost of Revenue | 22.77M | 25.83M | 35.84M | 49.05M | 49.65M |
| Gross Profit | 32.49M | 32.14M | 55.47M | 68.22M | 84.27M |
| Gross Margin | 58.8% | 55.4% | 60.8% | 58.2% | 62.9% |
| Research & Development | 870K | 915K | 1.34M | 2.39M | 2.1M |
| Selling, General & Admin | 35.47M | 37.98M | 64.29M | 77.91M | 74.89M |
| Operating Expenses | 36.34M | 38.89M | 65.63M | 80.29M | 76.99M |
| Depreciation & Amortization | 1.34M | 1.3M | 3.17M | 4.22M | 5.22M |
| EBITDA | (2.51M) | (5.43M) | 5.08M | (7.88M) | 15.9M |
| EBITDA Margin | -4.5% | -9.4% | 5.6% | -6.7% | 11.9% |
| Operating Income | (3.85M) | (6.76M) | (10.16M) | (12.07M) | 7.28M |
| Operating Margin | -7.0% | -11.7% | -11.1% | -10.3% | 5.4% |
| Interest Income | 0 | 31K | 149K | 0 | 94K |
| Interest Expense | 995K | 1.69M | 2.94M | 4.16M | 3.67M |
| Other Income / Expenses | (995K) | (1.66M) | 9.12M | (4.19M) | (283K) |
| Income Before Tax | (4.85M) | (8.42M) | (1.04M) | (16.26M) | 7M |
| Pre-Tax Margin | -8.8% | -14.5% | -1.1% | -13.9% | 5.2% |
| Income Tax Expense | 0 | 69K | (1.7M) | 187K | 2.03M |
| Net Income | (4.85M) | (8.49M) | 660K | (16.45M) | 4.97M |
| Net Margin | -8.8% | -14.6% | 0.7% | -14.0% | 3.7% |
| EPS (Basic) | (0.06) | (0.09) | 0.01 | (0.12) | 0.04 |
| EPS (Diluted) | (0.06) | (0.09) | 0.01 | (0.12) | 0.03 |
| Weighted Avg Shares | 85.46M | 94.09M | 119.09M | 133.67M | 139.53M |
| Weighted Avg Shares (Diluted) | 85.46M | 94.09M | 126.79M | 133.67M | 150.04M |
Xtant Medical Holdings, Inc.
AMEX:XTNT
Intrinsic Alpha fair value
Locked
Current Price
$0.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.